See more : CNB Corp. (CNBW) Income Statement Analysis – Financial Results
Complete financial analysis of SITE Centers Corp. (SITC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SITE Centers Corp., a leading company in the REIT – Retail industry within the Real Estate sector.
You may be interested
- Bit Brother Limited (BETSF) Income Statement Analysis – Financial Results
- Asahi Yukizai Corporation (4216.T) Income Statement Analysis – Financial Results
- Sino Prosper (Group) Holdings Limited (0766.HK) Income Statement Analysis – Financial Results
- Pan Asian Microvent Tech (Jiangsu) Corporation (688386.SS) Income Statement Analysis – Financial Results
- WealthNavi Inc. (WNAVF) Income Statement Analysis – Financial Results
SITE Centers Corp. (SITC)
About SITE Centers Corp.
SITE Centers is an owner and manager of open-air shopping centers that provide a highly-compelling shopping experience and merchandise mix for retail partners and consumers. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company, and is publicly traded on the New York Stock Exchange under the ticker symbol SITC.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 546.28M | 540.81M | 492.34M | 416.76M | 447.75M | 654.86M | 879.45M | 969.51M | 995.10M | 953.77M | 888.79M | 800.38M | 771.02M | 803.07M | 819.31M | 931.47M | 944.85M | 818.10M | 727.18M | 598.93M | 476.10M | 357.24M | 322.24M | 285.79M | 263.93M | 228.17M | 169.04M | 130.91M | 108.60M | 81.80M | 51.70M |
| Cost of Revenue | 165.72M | 169.98M | 152.79M | 138.40M | 139.66M | 207.99M | 250.92M | 277.08M | 293.69M | 281.11M | 255.35M | 233.08M | 235.80M | 246.16M | 254.47M | 257.12M | 133.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 380.55M | 370.82M | 339.56M | 278.36M | 308.09M | 446.87M | 628.53M | 692.42M | 701.41M | 672.66M | 633.44M | 567.30M | 535.22M | 556.91M | 564.84M | 674.35M | 811.52M | 818.10M | 727.18M | 598.93M | 476.10M | 357.24M | 322.24M | 285.79M | 263.93M | 228.17M | 169.04M | 130.91M | 108.60M | 81.80M | 51.70M |
| Gross Profit Ratio | 69.66% | 68.57% | 68.97% | 66.79% | 68.81% | 68.24% | 71.47% | 71.42% | 70.49% | 70.53% | 71.27% | 70.88% | 69.42% | 69.35% | 68.94% | 72.40% | 85.89% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 50.87M | 46.56M | 55.05M | 52.88M | 58.38M | 61.64M | 89.85M | 76.10M | 73.38M | 84.48M | 79.56M | 76.44M | 85.22M | 85.57M | 94.37M | 97.72M | 81.24M | 60.68M | 54.05M | 47.13M | 40.82M | 29.39M | 24.38M | 20.45M | 17.77M | 12.92M | 11.06M | 8.44M | 6.40M | 5.60M | 4.10M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -15.36M | -15.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 50.87M | 46.56M | 55.05M | 52.88M | 58.38M | 61.64M | 89.85M | 76.10M | 73.38M | 84.48M | 79.56M | 76.44M | 85.22M | 85.57M | 79.00M | 81.88M | 81.24M | 60.68M | 54.05M | 47.13M | 40.82M | 29.39M | 24.38M | 20.45M | 17.77M | 12.92M | 11.06M | 8.44M | 6.40M | 5.60M | 4.10M |
| Other Expenses | 0.00 | 203.55M | 185.77M | 170.67M | 165.09M | 242.10M | -95.36M | 39.62M | 31.23M | 19.65M | -6.63M | -17.88M | 222.66M | 222.86M | 227.19M | 242.03M | 328.08M | 401.31M | 349.01M | 281.19M | 436.63M | 326.34M | 302.62M | 114.62M | 104.34M | 204.15M | 139.39M | 111.53M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 45.87M | 250.11M | 240.82M | 223.55M | 223.47M | 303.74M | 446.85M | 465.62M | 475.43M | 487.31M | 397.63M | 325.23M | 307.88M | 308.44M | 321.55M | 596.87M | 409.32M | 461.99M | 403.06M | 328.32M | 477.45M | 355.73M | 326.99M | 135.07M | 122.11M | 217.07M | 150.45M | 119.96M | -43.60M | -33.40M | -23.10M |
| Cost & Expenses | 430.47M | 420.09M | 393.61M | 361.95M | 363.13M | 511.73M | 697.77M | 742.70M | 769.12M | 768.42M | 652.99M | 558.30M | 543.67M | 554.60M | 576.02M | 596.87M | 542.66M | 461.99M | 403.06M | 328.32M | 477.45M | 355.73M | 326.99M | 135.07M | 122.11M | 217.07M | 150.45M | 119.96M | -43.60M | -33.40M | -23.10M |
| Interest Income | 0.00 | 0.00 | 0.00 | 11.89M | 18.01M | 20.44M | 28.36M | 37.05M | 29.21M | 15.93M | 23.54M | 15.80M | 9.83M | 7.35M | 12.11M | 5.47M | 8.81M | 0.00 | 0.00 | 0.00 | 5.08M | 5.91M | 6.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 82.00M | 77.69M | 77.03M | 77.60M | 84.72M | 141.31M | 188.65M | 217.59M | 241.73M | 237.12M | 228.87M | 221.42M | 229.72M | 226.46M | 237.94M | 244.21M | 258.15M | 0.00 | 0.00 | 0.00 | 240.26M | 101.97M | 92.37M | 100.83M | 87.40M | 77.92M | 67.52M | 49.54M | 25.50M | 21.20M | 8.60M |
| Depreciation & Amortization | 212.46M | 203.55M | 185.77M | 170.67M | 165.09M | 242.10M | 346.20M | 389.52M | 402.05M | 402.83M | 318.08M | 248.78M | 222.66M | 222.86M | 227.19M | 242.03M | 224.38M | 193.53M | 170.70M | 132.65M | 95.22M | 78.37M | 64.49M | 54.20M | 52.44M | 43.18M | 32.31M | 25.06M | 23.60M | 17.40M | 10.90M |
| EBITDA | 339.27M | 361.16M | 372.32M | 263.06M | 323.04M | 338.23M | 577.39M | 667.87M | 656.21M | 634.70M | 514.62M | 456.09M | 230.11M | 252.22M | 244.64M | 337.90M | 629.59M | 549.64M | 494.82M | 403.26M | 417.48M | 222.98M | 64.49M | 196.19M | 415.86M | 359.46M | 285.80M | 218.10M | 175.80M | 132.60M | 85.70M |
| EBITDA Ratio | 62.11% | 66.78% | 75.62% | 63.12% | 72.15% | 51.65% | 53.41% | 73.10% | 68.87% | 66.55% | 64.99% | 65.47% | 61.42% | 60.30% | 60.63% | 52.91% | 66.63% | 67.24% | 68.39% | 67.63% | 19.72% | 22.36% | 18.54% | 71.70% | 73.60% | 23.68% | 28.03% | 27.51% | 161.60% | 162.10% | 165.76% |
| Operating Income | 339.27M | 157.61M | 186.55M | 92.39M | 157.95M | 96.12M | 637.03M | 692.42M | 701.41M | 672.66M | 221.41M | 196.76M | 214.91M | 65.10M | -119.34M | 169.00M | 261.41M | 250.78M | 282.99M | 271.23M | 240.26M | 101.97M | 92.37M | 100.83M | 87.40M | 77.92M | 67.52M | 49.54M | 25.50M | 21.20M | 8.60M |
| Operating Income Ratio | 62.11% | 29.14% | 37.89% | 22.17% | 35.28% | 14.68% | 72.44% | 71.42% | 70.49% | 70.53% | 24.91% | 24.58% | 27.87% | 8.11% | -14.57% | 18.14% | 27.67% | 30.65% | 38.92% | 45.29% | 50.46% | 28.54% | 28.67% | 35.28% | 33.11% | 34.15% | 39.94% | 37.85% | 23.48% | 25.92% | 16.63% |
| Total Other Income/Expenses | -71.50M | -188.46M | -12.29M | -62.36M | -41.49M | -76.27M | -456.83M | -273.51M | -490.55M | -194.30M | -510.01M | -113.39M | -250.28M | -211.28M | -198.46M | -279.60M | -71.96M | -182.52M | -139.86M | -86.31M | 73.04M | -38.81M | -74.95M | -67.88M | 0.00 | -314.76M | -252.10M | 0.00 | -152.20M | 0.00 | 0.00 |
| Income Before Tax | 267.77M | 169.61M | 126.97M | 37.72M | 102.48M | -108.44M | -402.67M | -10.41M | -231.60M | 22.96M | 4.60M | -13.62M | -41.54M | -146.18M | -317.80M | -89.94M | 189.90M | 173.59M | 184.26M | 184.31M | 240.26M | 101.97M | 92.37M | 100.83M | 87.40M | 77.92M | 67.52M | 49.54M | 25.50M | 21.20M | 8.60M |
| Income Before Tax Ratio | 49.02% | 31.36% | 25.79% | 9.05% | 22.89% | -16.56% | -45.79% | -1.07% | -23.27% | 2.41% | 0.52% | -1.70% | -5.39% | -18.20% | -38.79% | -9.66% | 20.10% | 21.22% | 25.34% | 30.77% | 50.46% | 28.54% | 28.67% | 35.28% | 33.11% | 34.15% | 39.94% | 37.85% | 23.48% | 25.92% | 16.63% |
| Income Tax Expense | 2.05M | 816.00K | 1.55M | 1.13M | 659.00K | 862.00K | 1.62M | 1.78M | 6.29M | 1.86M | 2.71M | 1.16M | 1.04M | 47.99M | -691.00K | -17.43M | -14.64M | -2.48M | 342.00K | 1.47M | -240.26M | -101.97M | -92.37M | -100.83M | -87.40M | -77.92M | -67.52M | -49.54M | -25.50M | -21.20M | -8.60M |
| Net Income | 265.70M | 168.72M | 124.94M | 35.72M | 100.70M | -109.30M | -241.69M | 60.01M | -72.17M | 117.28M | -10.18M | -25.82M | -15.85M | -209.36M | -356.59M | -57.78M | 276.05M | 253.26M | 282.64M | 269.76M | 240.26M | 101.97M | 92.37M | 100.83M | 87.40M | 77.92M | 67.52M | 49.54M | 25.50M | 21.20M | 8.60M |
| Net Income Ratio | 48.64% | 31.20% | 25.38% | 8.57% | 22.49% | -16.69% | -27.48% | 6.19% | -7.25% | 12.30% | -1.14% | -3.23% | -2.06% | -26.07% | -43.52% | -6.20% | 29.22% | 30.96% | 38.87% | 45.04% | 50.46% | 28.54% | 28.67% | 35.28% | 33.11% | 34.15% | 39.94% | 37.85% | 23.48% | 25.92% | 16.63% |
| EPS | 4.85 | 2.96 | 2.04 | 0.74 | 2.20 | -2.37 | -5.26 | 1.31 | -1.60 | 2.00 | -0.25 | -0.72 | -0.47 | -6.84 | -17.96 | -3.48 | 13.41 | 13.12 | 15.14 | 16.37 | 16.66 | 11.55 | 12.07 | 12.95 | 10.27 | 9.89 | 7.43 | 6.06 | 4.61 | 4.83 | 2.74 |
| EPS Diluted | 4.85 | 2.92 | 2.04 | 0.74 | 2.20 | -2.37 | -5.26 | 1.31 | -1.60 | 2.00 | -0.25 | -0.72 | -0.47 | -6.84 | -17.96 | -3.47 | 13.34 | 13.05 | 15.00 | 16.15 | 16.37 | 11.34 | 11.97 | 12.95 | 9.96 | 9.50 | 7.43 | 5.99 | 4.61 | 4.76 | 2.74 |
| Weighted Avg Shares Out | 52.36M | 53.25M | 52.00M | 48.33M | 45.76M | 46.13M | 45.92M | 45.66M | 45.11M | 44.76M | 40.80M | 35.88M | 33.78M | 30.59M | 19.85M | 16.62M | 16.76M | 15.09M | 15.02M | 13.38M | 11.35M | 8.83M | 7.65M | 7.79M | 8.51M | 7.88M | 7.18M | 7.66M | 5.53M | 4.39M | 3.14M |
| Weighted Avg Shares Out (Dil) | 52.41M | 53.47M | 52.29M | 48.44M | 45.81M | 46.13M | 45.92M | 45.70M | 45.11M | 44.76M | 40.80M | 35.88M | 33.93M | 30.59M | 19.85M | 16.64M | 16.85M | 15.18M | 15.17M | 13.56M | 11.55M | 8.99M | 7.72M | 7.79M | 8.78M | 8.20M | 7.18M | 7.66M | 5.53M | 4.45M | 3.14M |
Of 36 Dividend Power Dogs, 11 Are Buyable In November
Eleven of the 35 Dividend Power Dogs are recommended for their "safer" dividends, with free cash-flow yields exceeding dividend yields, making them ideal buys. The Dividend Power strategy focuses on high earnings yield and high dividend yield, creating a resilient...
SITE Centers Announces Tax Estimate for Curbline Properties Distribution
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Tax Estimate for Curbline Properties Distribution.
CBL & Associates Properties Vs. SITE Centers: Which Is The Better REIT For 2025
CBL & Associates Properties and SITE Centers are REITs focused on retail real estate, with reported occupancy rates indicating poor competitive dynamics. CBL funds a greater proportion of its capital structure with debt, but both companies have significant floating rate...
HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker
Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell response, with good overall safety Phase 2 trial evaluating eseba-vec/pembrolizumab combination...
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics' TCR-T PRAME franchise to target solid cancers
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Data continues positive trend as additional patients are enrolled in 3 cohorts Vaccine was safe and well tolerated by participants in all 3 cohorts Protocol defined immune responses were exhibited in over 70% of patients A Phase 2 study evaluating...
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation entitled “Pharmacodynamic and Response Biomarkers in the Monotherapy Arm of a Phase 1 Trial...
Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2 SK ) to the tumor microenvironment (TME), where it is conditionally activated by tumor-associated proteases
BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 08, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today is pleased to report...
Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that new preclinical data supporting the clinical development of its proprietary next generation antibody-drug conjugate (ADC) and innovative tetra-specific ANKET® will...
Source: https://incomestatements.info
Category: Stock Reports